A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)

• Status: Not yet recruiting
• Trial end date: 2023-06-15
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aristea Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Diagnosis of HS for at least 1 year prior to screening

• HS lesions must be present in at least 2 distinct anatomic areas

• A total AN count (sum of abscesses and inflammatory nodules) > 6 across all anatomical sites at both the screening and baseline visits

• Willing to use contraception for the duration of the study

Exclusion Criteria:

• Presence of other skin conditions which may interfere with study assessments

• Presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent TB) or history of infection within 4 weeks of screening

• Body Mass Index (BMI) >48kg/m2

• Breastfeeding or pregnant